ReviewInternational journal of hematology2011
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.
Review in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma.Current oncology reports · 2025Review
- The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma.International journal of molecular sciences · 2023Article
- Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients.International journal of cancer · 2021Article
- Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Risk Stratification in Multiple Myeloma.Current hematologic malignancy reports · 2016Review
- Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.Cancer biology & therapy · 2015Article
- Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma.Leukemia · 2014Article
- European perspective on multiple myeloma treatment strategies in 2014.The oncologist · 2014Review
- Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.International journal of hematology · 2013Article
- Enhancing cytokine-induced killer cell therapy of multiple myeloma.Experimental hematology · 2013Article
- Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.Leukemia · 2013Review
- Current approaches for the treatment of multiple myeloma.International journal of hematology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite improvement in therapeutic efficacy, multiple myeloma (MM) remains incurable with a median survival of approximately 10 years. Gene-expression profiling (GEP) can be used to elucidate the molecular basis for resistance to chemotherapy through global assessment of molecular alterations that exist at diagnosis, after therapeutic treatment and that evolve during tumor progression. Unique GEP signatures associated with recurrent chromosomal translocations and ploidy changes have defined molecular classes with differing clinical features and outcomes. When compared to other stratification systems the GEP70 test remained a significant predictor of outcome, reduced the number of patients classified with a poor prognosis, and identified patients at increased risk of relapse despite their standard clinico-pathologic and genetic findings. GEP studies of serial samples showed that risk increases over time, with relapsed disease showing GEP shifts toward a signature of poor outcomes. GEP signatures of myeloma cells after therapy were prognostic for event-free and overall survival and thus may be used to identify novel strategies for overcoming drug resistance. This brief review will focus on the use of GEP of MM to define high-risk myeloma, and elucidate underlying mechanisms that are beginning to change clinical decision-making and inform drug design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.